Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA)


You May Also Like

Retrophin Appoints Roy D. Baynes, M.D., Ph.D., to Board of Directors

SAN DIEGO, July 19, 2016 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment ...

146,000 Orion Corporation A shares converted into B shares

ORION CORPORATION      STOCK EXCHANGE RELEASE 1 AUGUST 2017 at 9.00 a.m. EEST               146,000 ...